Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coya Therapeutics, Inc. - Common Stock (NQ: COYA ) 7.040 -0.190 (-2.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Coya Therapeutics, Inc. - Common Stock < Previous 1 2 Next > Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study October 29, 2024 Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session October 29, 2024 Via Benzinga This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday September 16, 2024 Via Benzinga COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 August 12, 2024 COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace 7 Biotech Stocks to Put on Your Breakthrough Radar May 27, 2024 Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. Via InvestorPlace COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 March 19, 2024 Coya Therapeutics just reported results for the fourth quarter of 2023. Via InvestorPlace Coya Therapeutics February 29, 2024 100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha Via Talk Markets Analyst Expectations for Coya Therapeutics's Future July 17, 2023 Via Benzinga EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases May 27, 2024 Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,... Via Benzinga COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024 May 09, 2024 COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases February 05, 2024 Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access. Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session December 01, 2023 Via Benzinga How The Same Treatments May Work For Multiple Neurodegenerative Diseases September 21, 2023 Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. Via Talk Markets The Latest Analyst Ratings for Coya Therapeutics June 08, 2023 Via Benzinga Coya Therapeutics: Another Sucess May 16, 2023 The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. Via Talk Markets Why Coya Therapeutics Shares Are Shooting Higher Today May 16, 2023 Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session September 07, 2023 Via Benzinga Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation July 17, 2023 Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients Via Benzinga The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth July 12, 2023 Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this... Via Benzinga Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday June 08, 2023 Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close... Via Benzinga Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation June 07, 2023 Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session June 07, 2023 Via Benzinga Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket June 06, 2023 Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 06, 2023 It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! Via InvestorPlace 12 Health Care Stocks Moving In Thursday's After-Market Session June 01, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 May 18, 2023 Via Benzinga Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today May 16, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 16, 2023 Via Benzinga Positive Financials Along With Promising Clinical Results – Coya Therapeutics May 08, 2023 Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023 May 03, 2023 Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
